Treatment with recombinant KGF (Palifermin) is able to protect epithelial cells against a variety of injuries, including radiation-induced damage, and it has been approved by FDA for the treatment of severe oral mucositis that results from cancer radio and/or chemotherapy in patients with haematological or head and neck cancers [21,22]. Here, FGF7 is linked to cancer.